Menlo Park, California, July 10, 2012. 3-V Biosciences, Inc., announced today that George Kemble, PhD, Chief Scientific Officer, will present at the upcoming JMP Securities Healthcare Conference at the Peninsula Hotel in New York City. Dr. Kemble will provide an overview of 3‐V, including a discussion of both its lead program targeting the fatty acid synthase (FASN) pathway for the treatment of chronic hepatitis C virus (HCV) infection and the company’s discovery platform. Dr. Kemble’s presentation will take place on Friday, July 13 at 12:00pm.
FASN is a cellular enzyme with increased expression following infection with HCV and in several cancers. First‐generation FASN inhibitors have shown preclinical benefits in a variety of viral infections, including HCV, as well as in models of pancreatic, prostatic, breast and colorectal tumors, but their development has been hindered by poor bioavailability and systemic tolerability. 3‐V has discovered and is advancing proprietary FASN inhibitors with pharmaceutical properties that overcome the shortcomings of earlier generations of inhibitors, and have the potential to become potent therapeutics for chronic HCV and other indications.
About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company that discovers and develops antiviral therapeutics designed to have broad-spectrum activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The 3-V team applies an integrated approach with internal expertise in virology, biology, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.
For additional information on 3-V Biosciences, please visit www.3vbio.com.com.
Contact information
Stephen R. Brady Chief Business Officer 650‐561‐8600
